Loading...
•
Mar 31, 2023
ADMA Biologics Q1 2023 Earnings Report
ADMA Biologics achieved first-time Adjusted EBITDA profitability and increased revenue in Q1 2023.
Key Takeaways
ADMA Biologics reported a 96% year-over-year increase in total revenues, reaching $57 million in Q1 2023. The company achieved first-time Adjusted EBITDA profitability of $2.5 million and narrowed its net loss to $6.8 million. Based on these results, ADMA increased its 2023 total revenue guidance to exceed $220 million.
Achieved first-time Adjusted EBITDA profitability, totaling $2.5 million, ahead of the forecasted timeline.
Total revenues for the quarter increased by 96% year-over-year to $57 million.
Net loss improved by 73% year-over-year to $6.8 million.
Increased full year 2023 total revenue guidance to exceed $220 million.
ADMA Biologics
ADMA Biologics
Forward Guidance
ADMA Biologics anticipates full year 2023 total revenues to exceed $220 million and continued growth in Adjusted EBITDA profitability over the course of 2023.
Positive Outlook
- Full year 2023 total revenues are expected to exceed $220 million.
- Continued growth in Adjusted EBITDA profitability is anticipated throughout 2023.
- Accelerated net income profitability timelines may be achievable.
- Gross margins are forecasted to be in the range of 40-50% in 2024-2025.
- Net income margins are forecasted to be in the range of 20-30% in 2024-2025.
Challenges Ahead
- Guidance framework considers several macroeconomic uncertainties.
- Future success depends on ADMA's demand trends and margin dynamics sustaining.
- Achieving source plasma self-sufficiency is dependent on obtaining FDA approval of additional plasma collection centers.
- Future success depends on the success of BIVIGAM and ASCENIV in future periods.
- The ability to realize benefits from the higher production scale of ASCENIV is dependent on timing.